OncoVAX (autologous cancer vaccine) / Vaccinogen - LARVOL DELTA

A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer (clinicaltrials.gov) - P3 | N=550 | Not yet recruiting | Sponsor: Vaccinogen Inc | Trial completion date: Jul 2022 ➔ Aug 2033 | Trial primary completion date: Jul 2020 ➔ Aug 2031

Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. (PubMed, BMJ Open) - "Recently, two autologous cell vaccines Vigil and OncoVAX have made it to phase III clinical trials...Results will be submitted to peer-reviewed journals for publication and presented to relevant stakeholders and scientific meetings. CRD42019140187."

Journal • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Oncology